Results 221 to 230 of about 106,290 (280)

Intratumoral Proton Density Fat Fraction Predicts the Outcome of HAIC Combined With PD‐1 Inhibitors in Advanced Hepatocellular Carcinoma

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background and Aims This study aimed to explore the predictive value of intratumoral proton density fat fraction (PDFF) and the clinical efficacy of hepatic arterial infusion chemotherapy (HAIC) combined with anti‐programmed cell death protein 1 (anti‐PD‐1) therapy in advanced hepatocellular carcinoma (HCC).
Yujie Ye, Yunzheng Li, Yanjun Lu, Yanchao Xu, Laizhu Zhang, Yican Zhu, Huan Li, Binghua Li, Min Zhou, Decai Yu   +9 more
wiley   +1 more source

A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics. [PDF]

Cancer Res Commun
Sakshaug BC, Haukaas TH, Folkesson E, Ringers C, Bwanika HCH, Bergstrøm IA, Sigfúsdóttir MS, Trøen HH, Sperstad SB, Stornes T, Klinkenberg G, Visnes T, Flobak Å.   +12 more
europepmc   +1 more source

Preoperative Biomarker Panel With Fibrinogen, FVIII, and CA 19–9 as a Tool for Prognostic Evaluation in Neoadjuvant‐Treated Pancreatic Ductal Adenocarcinoma

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Pancreatic ductal adenocarcinoma (PDAC) is highly thrombogenic and lethal, with rising incidence. Combining carbohydrate antigen (CA) 19–9, fibrinogen, coagulation factor VIII (FVIII), albumin, and alkaline phosphatase (ALP) as a diagnostic panel improves diagnostics.
Nora Mattila, Riitta Lassila, Harri Mustonen, Caj Haglund, Hanna Seppänen   +4 more
wiley   +1 more source

Comparative efficacy and safety of S-1 plus oxaliplatin with sintilimab vs. paclitaxel-S-1-oxaliplatin and docetaxel-oxaliplatin-5-fluorouracil as first-line therapy for advanced gastric cancer. [PDF]

Anticancer Drugs
Wang Y, Ma B, Zhang C, Wang Y, Pan T, Zhao C, Cai B, Yu P, Guo B, Ma J.   +9 more
europepmc   +1 more source

Clinical Outcomes of the Alternative GAMMA Regimen in Relapsed Germ Cell Tumours

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Following promising results in a phase II trial evaluating GAMMA as salvage therapy for relapsed germ cell tumours (GCT) who had progressed on cisplatin‐based chemotherapy, the GAMMA regimen was adopted into clinical practice at St Bartholomew's Hospital.
Nasreen Abdul Aziz, Kenrick Ng, Prabhakar Rajan, Jonathan Shamash   +3 more
wiley   +1 more source

Oxaliplatin-induced porto-sinusoidal vascular disease manifesting as recurrent gastroesophageal variceal hemorrhage: a case report. [PDF]

Front Med (Lausanne)
Zhao R, Liang C, Zhuang Z, Xia Y, Lu J, Zhang Y.   +5 more
europepmc   +1 more source

Feasibility Study of Trifluridine/Tipiracil and Zolbetuximab as Third‐ or Later‐Line Chemotherapy for CLDN18.2‐Positive and HER2‐Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Study Protocol

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Zolbetuximab is an anti‐claudin18.2 (CLDN18.2) antibody, and the addition of zolbetuximab in combination with fluoropyrimidine and oxaliplatin as a first‐line treatment for CLDN18.2‐positive and HER2‐negative gastric or gastroesophageal junction adenocarcinoma has been shown to improve survival.
Osamu Maeda, Chie Tanaka, Kazuhiro Furukawa, Kazushi Miyata, Dai Shimizu, Shizuki Sugita, Koki Nakanishi, Takashi Hirose, Kazuyuki Mizuno, Fumie Kinoshita, Yachiyo Kuwatsuka, Masahiko Ando, Mitsuro Kanda, Hiroki Kawashima, Yuichi Ando   +14 more
wiley   +1 more source

Vascular Dysfunction in Colorectal Cancer: Scoping Review of Current Evidence for Guiding Future Research. [PDF]

J Gastrointest Cancer
DeJonge SR, DuBose NG, Gantt G, Tussing-Humphreys L, Motl RW.   +4 more
europepmc   +1 more source